Table 1 Comparison of urodynamic parameters and IPSS/QoL at V1a, V2b and V3c

From: Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study

  V1 V2 V3 P-value
     V1 vs V2 V1 vs V3
IPSS 15.60±7.79 11.29±5.77 9.01±4.86 <0.001 <0.001
QoL 3.22±0.89 2.86±0.90 2.42±0.96 0.001 <0.001
Qmax (ml s−1) 14.54±3.26 14.42±3.35 14.55±3.17 0.098 0.472
PVR (ml) 22.10±28.75 17.66±15.07 18.71±16.65 0.229 0.343
  1. Abbreviations: IPSS, international prostate symptom score; PVR, post-voiding residual urine volume; Qmax, peak urine flow rate; QoL, quality of life.
  2. aAt the start of the study.
  3. b4 weeks after the initial administration of the drug.
  4. c8 weeks after the initial administration of the drug.